title: Review of F-FDG Synthesis and Quality Control.
abstract: This review article covers a concise account on fludeoxyglucose ((18)F-FDG) synthesis and quality control procedures with emphasis on practical synthesis Currently, (18)F-FDG is the most successful PET radiopharmaceutical so far. The advancement in synthesis and quality control of (18)F-FDG, together with its approval by the US FDA and the availability of reimbursement, are probably the main reasons for the flourish of clinical PET over the last 20 years. (18)F-FDG can be synthesised by either electrophilic fluorination or nucleophilic fluorination reaction. Nucleophilic fluorination using mannose triflate as precursor and Kryptofix or tetrabutylammonium salts (TBA) is widely used because of higher yield and shorter reaction time. The quality control requirements of (18)F-FDG can be found in United States Pharmacopeia (USP), British Pharmacopeia (BP), European Pharmacopeia (EP) and the Chemistry, Manufacturing, and Controls (CMC) section from United States Food and Drug Administration (US FDA) PET draft guidance documents. Basic requirements include radionuclidic identity, radiochemical purity, chemical purity, pH, residual solvent, sterility, and bacterial endotoxin level. Some of these tests (sterility, endotoxins and radionuclidic purity) can be finished after the (18)F-FDG has been released. Although USP, BP and EP do not require filter membrane integrity test, many laboratories perform this test as an indirect evident of the product sterility. It is also interesting to note that there are major differences in (18)F-FDG quality requirements among USP, BP, and CMC.
authors: S
authors: S
authors: Yu
references: J Nucl Med. 1982 Oct;23(10):918-22
references: 7119887
references: Am J Physiol. 1970 Mar;218(3):743-50
references: 4905483
references: Nucl Med Biol. 1993 Apr;20(3):367-9
references: 8485498
references: J Nucl Med. 2002 Nov;43(11):1495-506
references: 12411554
references: J Nucl Med. 1980 Aug;21(8):750-7
references: 7400831
references: J Lab Clin Med. 1989 Sep;114(3):306-11
references: 2671216
references: J Nucl Med. 1978 Oct;19(10):1154-61
references: 214528
references: J Biochem Biophys Methods. 1989 Mar;18(2):97-104
references: 2663963
references: J Nucl Med. 1984 Mar;25(3):333-7
references: 6699724
references: Haemostasis. 1978;7(2-3):183-8
references: 658779
references: J Biochem Biophys Methods. 1991 Feb-Mar;22(2):93-100
references: 2061565
references: J Nucl Med. 1983 Aug;24(8):718-21
references: 6683752
references: J Nucl Med. 1986 Feb;27(2):235-8
references: 3712040
references: Int J Rad Appl Instrum A. 1986;37(12):1181-8
references: 3028984
references: Eur J Cancer. 1973 Jul;9(7):463-70
references: 4803223
references: Semin Nucl Med. 2002 Jan;32(1):6-12
references: 11839070
references: Ann Acad Med Singap. 2004 Mar;33(2):146-54
references: 15098627